Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Tiludronate

Known as: (chloro-4-phenyl)thiomethylene biphosphonate, (chloro-4-phenyl)thiomethylene bisphosphonate 
National Institutes of Health

Related topics

Related topics

5 relations
DiphosphonatesDrug AllergyPaget Disease Extramammary

Narrower (1)

Tiludronate disodium

Broader (1)

tiludronic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
From Molds and Macrophages to Mevalonate: A Decade of Progress in Understanding the Molecular Mode of Action of Bisphosphonates
  • M. Rogers
  • Calcified Tissue International
  • 2004
  • Corpus ID: 24438016
Although bisphosphonates were first used as therapeutic agents to inhibit bone resorption in the early 1970s, their mode of… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Review
2003
Review
2003
New insights into the molecular mechanisms of action of bisphosphonates.
  • M. Rogers
  • Current pharmaceutical design
  • 2003
  • Corpus ID: 22525479
Bisphosphonates are currently the most important and effective class of anti-resorptive drugs available, but the exact molecular… 
Highly Cited
2000
Highly Cited
2000
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI‐298
Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their… 
Review
2000
Review
2000
Oral bisphosphonates
This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer… 
Review
1999
Review
1999
Bisphosphonates: from the laboratory to the clinic and back again.
Bisphosphonates (BPs) used as inhibitors of bone resorption all contain two phosphonate groups attached to a single carbon atom… 
Highly Cited
1997
Highly Cited
1997
Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.
Signaling pathways mediated by tyrosine phosphorylation and dephosphorylation have been reported to be involved in the regulation… 
Highly Cited
1996
Highly Cited
1996
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+‐ATPase
Although bisphosphonates have been shown to be potent inhibitors of osteoclast‐mediated bone resorption in vivo and in vitro and… 
Highly Cited
1995
Highly Cited
1995
A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
The mechanism of action of tiludronate [(4-chlorophenyl)-thiomethylene bisphosphonate] on osteoclastic bone resorption was… 
Highly Cited
1995
Highly Cited
1995
Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
OBJECTIVE To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of… 
Highly Cited
1989
Highly Cited
1989
PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE
76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE